CJC-1295 research guide for Mogapi. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Unlike common nutraceuticals stocked in every health store, CJC-1295 is distributed via a global research peptide market that Mogapi residents navigate through international suppliers. What this means for Mogapi researchers is that your location matters far less than your ability to verify analytical documentation — and those quality checks are accessible to anyone. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. The sections below cover what Mogapi researchers need to know about sourcing, verifying, and handling CJC-1295 for legitimate research applications.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Mogapi comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
Evaluating CJC-1295 vendors starts with the COA: locate the batch-specific certificate prior to buying, not after. The HPLC chromatogram is the most important document in the COA: it should show a large primary peak representing CJC-1295, with minimal secondary peaks representing impurities — purity should be stated as ≥98%. Strong quality indicators beyond COA quality: multi-year operating history, responsive technical support who understand testing methodology, and shipping with desiccant and appropriate cold protection. For Mogapi researchers making a first CJC-1295 purchase: apply these quality criteria before ordering, start with a modest quantity, and confirm the COA batch number matches your received product before use.
Order CJC-1295 — ships to Mogapi
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Reconstitute CJC-1295 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg in 2mL gives a 2.5mg/mL solution — providing 25mcg per unit measured on a 100-unit syringe. Verify the endotoxin level in your CJC-1295 batch COA before any injectable research application — look for results reported in endotoxin units per mg or mL and verify they are within the acceptable range for your research context. The research literature on CJC-1295 should be reviewed carefully before beginning any research — study methodologies, dosing, and endpoints vary significantly and not all findings translate directly.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
